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Background: Extracellular purines, in particular adenosine (Ado) and adenosine-tri-
phosphate, are critical immunoregulatory molecules. Expression and activity of purine
ecto-enzymes on B cells in neonatal and adult blood may influence their function and
has been incompletely characterized.
Methods: Mononuclear cells were isolated from human neonatal (cord blood) or adult 
(peripheral blood) subjects and evaluated directly by flow cytometry for expression of
purine ecto-enzymes. Additionally, B cell subsets were isolated from mononuclear cell
fractions by fluorescence-activated cell sorting and gene transcription of purine ecto-en-
zymes (CD39 and CD73), Ado deaminase (ADA1), purine nucleoside phosphorylase,
and select purine receptors (A2a) were evaluated by reverse transcription followed by
qRT-PCR. Immuno-magnetic-bead isolated naïve B cells were evaluated for enzymatic 
activity by incubation with radio-labeled purines followed by thin-layer chromatography, 
and subsequent B cell Ado acquisition was evaluated by liquid scintillation quantitation 
of radio-labeled Ado uptake.
results: Relative to their adult counterparts, neonatal circulating naïve B cells were
markedly and selectively deficient in CD73 as observed by gene transcription, surface
protein expression, and enzyme activity. Neonatal naïve B cell deficiency of CD73
expression significantly impaired their capacity to acquire extracellular purines for purine 
salvage.
conclusion: Human neonatal circulating naïve B cells are selectively deficient in CD73, 
impairing extracellular purine acquisition and potentially contributing to impaired B cell
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inTrODUcTiOn
B cells develop from pluripotent precursors in the bone marrow, enter circulation as mature naïve B cells, 
and eventually traffic through lymphoid and non-lymphoid tissues in search of antigen. Activation by 
specific antigen along with helper T cells in lymphoid tissue can trigger further maturation (1), clonal 
proliferation, changes in the immunoglobulin (Ig) locus, and antibody (Ab) production and secretion. 
While Ab production plays a critical role in protection from infectious agents, other functions of 
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B cells, including cytokine production and antigen presentation to 
T cells (2, 3), help shape immunity as well. Neonates are particu-
larly susceptible to infection, in part reflecting distinct immunity 
in early life (4). Among the differences in immunity in early life, 
neonatal B cell function is distinct from that of adults (5, 6), but the 
underlying mechanisms are incompletely characterized.
Of note, purine metabolism plays an important role in 
regulating many B cell functions. Extracellular purine di- and tri-
phosphates are dephosphorylated by CD39 (ENTPD1) and other 
related ecto-enzymes generating adenosine mono-phosphate 
(AMP), while CD73 (ecto-5′ nucleotidase) dephosphorylates 
AMP generating adenosine (Ado), an immunoregulatory 
molecule that can be further metabolized by Ado deaminase 
(7). Genetic deficiency of Ado deaminase (ADA1) or purine 
nucleoside phosphorylase (PNP) disrupts intracellular purine 
metabolism and leads to severe-combined immunodeficiency 
(SCID) with insufficiency of functional lymphocytes (8, 9). 
Additionally, purine nucleoside analogs that disrupt intracellular 
purine salvage inhibit B cell proliferative responses (10). B cells 
from patients with common variable immunodeficiency (CVID), 
characterized by limited Ab production and frequent infections, 
have low expression of CD73 and, thus, impaired metabolism of 
extracellular purines (11). Additionally, in a given human adult 
individual, subsets of B cells with reduced CD73 expression have 
a more limited capacity to undergo class-switch recombination 
in vitro (11).
Purine enzyme expression, including CD73, is regulated dur-
ing lymphocyte maturation. In mice, CD73 is expressed primarily 
on B cells that have undergone class-switch recombination (12), 
and is a marker of memory (13, 14). Murine germinal center B 
cells express increasing levels of CD73, whereas plasmablasts 
and bone marrow plasma cells have little to no CD73 expression 
(15). In humans, AMPase activity was lower on circulating total 
B cells in newborn cord than adult blood (16), with neonatal B 
cell AMPase activity reaching adult levels by 6–12 months of age 
(17). However, these studies did not clarify if the differences were 
due to higher activity in adult cells as a result of greater expression 
of CD73 [or tissue non-specific alkaline phosphatase (TNAP)] on 
memory B cells, which are present at significantly lower levels in 
newborns.
To gain insight into the ontogeny of purine metabolism on 
human B cells, we sought to more fully characterize the expres-
sion of purine enzymes on circulating neonatal and adult B cell 
subsets, and to evaluate the impact of CD73 expression on B cell 
acquisition of extracellular purines. We found that circulating 
human neonatal B cells are deficient in CD73 expression and 




Peripheral blood was collected after informed consent from 
healthy adult volunteers according to Boston Children’s Hospital 
Institutional Review Board-approved protocols (Boston, MA, 
USA; mean age 31.8 years, range 23–40 years), and newborn cord 
blood (mean gestational age 39.1 weeks, range 37.4–41.1 weeks) 
was collected immediately after elective cesarean section delivery 
(epidural anesthesia) of the placenta. Births to HIV-positive or 
febrile mothers were excluded. Human experimentation guide-
lines of the US Department of Health and Human Services, the 
Brigham and Women’s Hospital, Beth Israel Medical Center, and 
Boston Children’s Hospital were observed, following protocols 
approved by the local institutional review boards. Number of 
repeats (N) indicates number of unique human subjects evaluated 
per experimental procedure, no subject was studied more than 
once in each of the different experiments. Blood was collected 
into syringes containing a final concentration of 20 U/mL heparin 
(Sagent Pharmaceuticals; Schaumberg, IL, USA) and was used 
within 2 h of collection.
Mononuclear cell isolation and Magnetic 
Bead naïve B cell isolation
Peripheral blood mononuclear cells (PBMC) or cord blood 
mononuclear cells (CBMC) were isolated from heparinized 
whole blood by Lymphoprep (Accurate Chemical; Westbury, NY, 
USA) density gradient centrifugation. Non-naïve B cells (CD27+ 
B cells, T cells, NK cells, monocytes, dendritic cells, granulocytes, 
platelets, and erythroid cells) were labeled with a cocktail of bioti-
nylated CD2, CD14, CD16, CD27, CD36, CD43, and CD235a 
Abs and magnetically labeled with Anti-Biotin MicroBeads for 
depletion (Naïve B Cell Isolation Kit II, human, Miltenyi Biotec, 
Auburn, CA, USA). To improve purity, unlabeled flow-through 
cells were subsequently labeled with CD19 microbeads (Miltenyi 
Biotec) for isolation of highly pure naïve B cell populations. 
All assayed samples had naïve B cell purities of >90% [mean 
CD20+IgD+ purity: 96% adults and 95% for newborns, purity was 
evaluated by flow cytometry as described below but with CD20 
(APC-Cy7) antibodies instead of CD19 targeting antibodies]. 
Magnetic bead-isolated naïve B cells were utilized in enzyme 
activity and purine uptake assays.
Flow cytometry
Mononuclear cells were stained with Abs (BD Biosciences, 
Frederick, MD, USA) targeting CD19 (APC-Cy7), CD24 (PE-
Cy7), CD27 (PerCP-Cy5.5), CD38 (BV-605), IgD (BV-421), CD39 
(FITC), and CD73 (APC). Stained cells were stained in PBS for 
30 min at 4°C. Cells were then washed with PBS before fixation 
with 4% paraformaldehyde (Alfa Aesar, Ward Hill, MA, USA). 
Fluorescent intensities were detected using an LSR Fortessa flow 
cytometer (BD Biosciences), and gating strategies depicted in 
Figure 1 were based on previous characterization of B cell subsets 
from human pediatric and adult subjects (18). Compensation was 
performed in DIVA software (BD Biosciences) and fluorescent 
intensities were analyzed using Flowjo software version 10 (Tree 
Star Inc., Ashland, OR, USA).
Fluorescence-activated cell sorting
Fluorescence-activated cell sorting (FACS) was utilized to 
acquire highly pure B cell subsets for analysis of mRNA expres-
sion. Mononuclear cells were stained with Abs  targeting CD19 
(APC-Cy7), CD24 (PE-Cy7), CD27 (PerCP-Cy5.5), CD38 (BV-
605), and IgD (BV-421). Cells were sorted using a FACSAria II 
FigUre 1 | gating strategy for B cell flow cytometry. Briefly, CD19+ B cells were analyzed for differential expression CD24/CD38 (transitional naïve B cells 
CD38++CD24++) or IgD/CD27 (naïve B cells IgD+CD27−, IgD+ memory B cells IgD+CD27+, switched memory B cells and plasma cells are both IgD−CD27+). 
CD19+CD27+IgD− cells were further analyzed by CD38 expression (switched memory B cells CD38±, plasmablasts CD38++). A similar gating strategy was used for 
fluorescence-activated cell sorting (FACS) with the exception that each population was a more conservative independent gate inside of each quadrant for the CD27 
vs. IgD parameters Transitional B cells were not flow sorted.
3
Pettengill and Levy Low CD73 Expression on Neonatal B Cells
Frontiers in Immunology | www.frontiersin.org March 2016 | Volume 7 | Article 121
cell sorter (BD Biosciences) utilizing the gating strategy described 
above (Figure 1). In brief, B cells were CD19+, and subsets were 
naïve B cells (IgD+CD27−), IgD+ memory (IgD+CD27+), class-
switched memory (IgD−CD27+CD38±), and plasmablasts (IgD
−CD27+CD38++). B cell subpopulations were sorted into tubes 
containing RPMI 1640 media (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% Fetal Bovine Serum (FBS, HyClone, 
VWR; Radnor, PA, USA), centrifuged at 500×  g for 10  min, 
and pellets resuspended in Buffer RLT (Qiagen GmbH; Hilden, 
Germany) for RNA isolation.
rna Purification and cDna synthesis
Total RNA was isolated from sorted B cell subpopulations 
using the RNeasy Mini Kit with RNase-free DNase treatment 
(Qiagen GmbH; Hilden, Germany). Up to 300  ng of mRNA 
was reverse-transcribed to cDNA using the RT2 First-strand Kit 
(SABiosciences, Frederick, MD, USA), according to the manu-
facturer’s instructions.
qrT-Pcr
Expression levels of selected genes were assessed by qRT-PCR 
analysis using an ABI 7300 real-time PCR system machine 
and software (Applied Biosystems; Foster City, CA, USA). The 
baseline adjustment method of the ABI 7300 software was used 
to determine the cycle threshold (Ct) in each reaction. A melting 
curve was constructed for each primer pair to verify the pres-
ence of one amplicon-specific peak and the absence of primer 
dimerization. All samples were amplified in triplicates and the 
mean was used for further analysis. Relative expression of target 
gene mRNA was compared to that of the “housekeeping” gene 
β-actin (actB) using the  ΔΔ-Ct method.
Primer sequences
ADA1, Forward 5′-TGGTTTCAGGCTTGATGGA-3′, Reverse 5′- 
GGCAGAGACCCACCGAG-3′; PNP, Forward 5′-GAAGCCAT 
TCTCAGTGTTCT-3′, Reverse 5′-TTGCTCAGTTCAGCATAG 
CG-3′; CD73, Forward 5′-TTTGGCCTCTTTGAGGAGTG-3′, 
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Reverse 5′-GGCACTATCTGGTTCACCGT-3′; CD39, Forward 
5′-CCCACAGCAAGCAAAGCTA-3′, Reverse 5′-GGGGAAAG 
ACGAGGAAAGAG-3′; TNAP, Forward 5′-ACCTGCTTTAT 
CCCTGGAGC-3′, Reverse 5′-CTTGTGCCTGGACGGAC-3′; 
adenosine receptor A1 (ADORA1), Forward 5′-CTGCCTGAC 
TGTTCTGTCCA-3′, Reverse 5′-GCCTGTTCTGAATCCCAGA 
G-3′; adenosine receptor A2a (ADORA2a), Forward 5′-GATGG 
CAATGATGCCCTTAG-3′, Reverse 5′-TCCATCTTCAGTCTC 
CTGGC-3′; adenosine receptor A2b (ADORA2b), Forward 
5′-TCCCCGTGACCAAACTTTTA-3′, Reverse 5′-TGACTTCT 
ACGGCTGCCTCT-3′; adenosine receptor A3 (ADORA3), 
Forward 5′-CAGTTTCATGTTCCAGCCAA-3′, Reverse 5′-ATC 
GCTGTGGACCGATACTT-3′; actB, Forward 5′-GTTGTCGAC 
GACGAGCG-3′, Reverse 5′-GCACAGAGCCTCGCCTT-3′.
Purine enzyme Uptake assay
Magnetic bead purified naïve B cells were resuspended in RPMI 
1640 culture media (without serum) to a final density of 5 × 107 
cells/mL, and warmed to 37°C. To 20 μL of cell suspension was 
added 2.5 μL of RPMI or 2.5 μL of recombinant human CD73 
(prepared in RPMI at 1:500 from manufacturer’s stock), then 
2.5 μL of 500 μM 14C-AMP (Moravek Biochemicals). After gentle 
mixing, the suspension was returned to a heating plate at 37°C 
(final concentration of 4 × 107 cells/mL and 50 μM 14C-AMP). 
After 3 min of incubation, samples were centrifuged at 1000× g for 
1 min. Ten microliters of supernatant were added to a microtube 
containing 30 μL of a solution containing 50 mM EDTA (Gibco), 
and 30 μM EHNA (ADA1 inhibitor, Tocris), in PBS (Invitrogen) 
and this volume was frozen at −20°C for subsequent thin-layer 
liquid chromatography. The remaining supernatant was trans-
ferred to a glass vial, and 20 μL of RPMI was added gently to 
the cell pellet that was quickly centrifuged at 1000× g for 1 min. 
The supernatant was transferred to the original supernatant glass 
vial for that sample, then the cell pellet was resuspended in 20 μL 
of fresh RPMI and the cells were transferred to a new glass vial. 
Six milliliters of liquid scintillation cocktail (Opti-Fluor, Perkin 
Elmer) were added to the glass vials, which were mixed thoroughly 
before analyzing C-14 counts per minute (CPM) on a Packard 
Bioscience Tri-Carb 2100TR liquid scintillation analyzer.
Thin-layer chromatography
Controls (14C-AMP, 14C-Ado, and 14C-inosine  –  Moravek 
Biochemicals) and samples were applied to silica gel matrix thin-
layer chromatography plates (Sigma-Aldrich) and migrated until 
the solvent (6:3:1 2-propanol:ammonium hydroxide:D H20) front 
reached 4 cm beyond the application site. Plates were dried and 
incubated in a storage phosphor screen cassette overnight, after 
which the screens were analyzed on a GE Storm 860 Imager. 
Scanned images were evaluated using the ImageJ software package 
gel analysis tools (version 1.49, Wayne Rasband, National Institutes 
of Health, USA) to quantify densitometry relative to a dilution 
series of 14C-Ado run on the same plates as experimental samples.
statistical analysis
Statistical tests described in the figure legends were performed 
using GraphPad Prism version 5.0b for Mac.
resUlTs
Previous studies by our group and others had raised the  possibility 
that compared to circulating total adult B cells (all CD19+ cells), 
total newborn B cells have distinct (lower) expression of both 
CD73 and CD39 (19) and lower AMPase activity (17). As adult 
circulating B cells include a large number of activated and memory 
B cells, and newborns do not have significant numbers of these 
cells, we sought to evaluate the expression of CD73, CD39, and 
other receptors or enzymes involved in the generation of Ado or 
Ado signaling on subsets of B cells in circulation from human adult 
and newborn study participants. Gating strategies for evaluating 
or isolating subsets of B cells are shown in Figure 1, and have been 
previously described (18).
Flow cytometry revealed that CD39 surface expression was 
similar on circulating nave B cells from adults or newborns 
(Figures 2A,C), but that CD73 expression was strikingly lower 
on circulating neonatal naïve B cells (Figures 2B,D). Deficiency 
of CD73 expression on newborn naïve B cells was similar on 
transitional naïve B cells (CD24++) and mature naïve B cells 
(CD24+, data not shown). We also evaluated mRNA expression 
of the primary enzymes involved in extracellular Ado generation 
(CD39, CD73, TNAP), enzymes involved in intra- and extracel-
lular purine nucleoside metabolism (ADA1, PNP), and all four 
receptors for extracellular Ado receptors (A1, A2a, A2b, and A3), 
in subsets of circulating B cells from adults and newborns. Cells 
were sorted by FACS to isolate pure populations of naïve B cells 
(CD19+IgD+CD27−) from newborn cord blood samples, and 
naïve IgD+ memory (CD19+IgD+CD27+), class-switched memory 
(CD19+IgD−CD27+CD38±), and plasmablasts (CD  9+IgD−CD2
7+CD38++), from adult peripheral blood. Very low signal for a 
minority of samples or no signal at all was detected for TNAP or 
Ado receptors A1, A2b, or A3 (data not shown). mRNAs encod-
ing ADA1 and PNP were consistently detected at similar levels 
between newborn and adult naïve B cells. The only Ado receptor 
for which mRNA was consistently detected was the A2a receptor 
that was similarly expressed in newborns and adult naïve B cells. 
CD39 mRNA was similar between newborn and adult naïve B 
cells, while CD73 mRNA was significantly lower on newborn 
naïve B cells (Figure 3), as had been observed for surface protein.
On adult circulating B cells, CD39 expression was elevated with 
markers of further activation and differentiation (Figures 4A,C), 
being higher on CD27+ B cells than on naïve B cells, and highest 
on plasmablasts (IgD−CD24−CD27+CD38++). By contrast, CD73 
expression was highest on naïve and class-switched circulating 
B cells, with subpopulation of IgD+ memory and class-switched 
cells having diminished surface expression of CD73, and plas-
mablasts having consistently low expression (Figures  4B,D). 
CD39 and CD73 expression was similar on transitional B cells 
(IgD+CD24++CD27−CD38++) and naïve counterparts for both 
newborn and adult subjects (data not shown). CD39 and CD73 
mRNA expression in subsets of adult circulating B cells correlated 
with detection of surface protein by flow cytometry (Figure  4). 
CD39 was most highly expressed on plasmablasts (Figures 4C,E). 
CD73 expression is regulated with B cell maturation, with the high-
est levels on naïve cells, and consistent reduction of mRNA and 
protein on IgD+ memory cells. Class-switch recombined memory 
FigUre 2 | neonatal naïve B cells have a significant deficiency of cD73 surface expression. Flow cytometry analysis reveals that CD39 surface expression 
was similar on naïve B cells from neonatal cord blood or adult peripheral blood (a,c), but CD73 is strikingly deficient on neonatal naïve B cells (B,D). Data shown in 
(a,B) are from one independent experiment, representative of N = 5–9 subjects for each target, respectively. (c,D) present mean fluorescent intensity (MFI) for N = 5 
newborn subjects and 9 adult subjects, bars represent population means and error lines are the standard error mean (SEM), **p < 0.01, two-tailed Student’s t-test.
FigUre 3 | human neonatal naïve B cells are selectively deficient in 
cD73 mrna compared to adult counterparts. Adult and newborn 
circulating naïve B cells were isolated by FACS and evaluated for mRNA 
expression of purine enzymes CD39, CD73, ADA1, PNP, and the Ado 
receptor A2a. N = 8 (neonatal) or 10 (adult), horizontal lines represent the 
mean, **p < 0.01, two-tailed Student’s t-test.
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B cells had similar levels of CD73 expression to naïve cells, whereas 
plasmablasts demonstrated very low levels of both mRNA and 
protein expression for CD73 (Figures 4D,F). mRNA expression 
of purine enzymes ADA1 and PNP was also detected in all subsets 
of adult B cells, but differences were not statistically significant in 
other subsets relative to adult naïve B cells (data not shown).
All human cells express equilibrative and concentrative 
nucleoside transporters (ENTs and CNTs, respectively) capable 
of acquiring purine nucleosides from the extracellular environ-
ment, whereas charged nucleotides are not transported across 
cell membranes. Extracellular purines have important signaling 
functions but can also be utilized for purine salvage if they can 
be acquired as nucleosides. Extracellular adenine nucleotides 
must be completely dephosphorylated prior to acquisition. While 
CD39 is expressed on both newborn and adult naïve B cells at 
similar levels, CD73 deficiency on newborn naïve B cells may 
limit the purine acquisition rate from the extracellular environ-
ment for purine salvage. We tested this by isolating naïve B cells 
from newborn cord blood and adult peripheral blood using 
magnetic bead isolation, and exposing them to radio-labeled 
AMP (C14) to evaluate the de-phosphorylation of AMP, and 
additionally to evaluate the cellular acquisition the generated C14-
Ado. Adult naïve B cells dephosphorylated nearly all of the AMP 
within 3 min, which could not be increased by addition exog-
enous recombinant human CD73 (rCD73), whereas newborn 
naïve B cells had a lower rate of AMPase activity that could be 
enhanced considerably by addition of exogenous rCD73 enzyme 
(Figures 5A,B). At baseline, the rate of C14-Ado acquisition by 
newborn naïve B cells was significantly lower than that for adult 
counterparts (Figure  5C). The difference in purine acquisition 
was due to deficiency of CD73 expression on the newborn naïve 
B cells, as addition of exogenous enzyme increased their C14-
Ado acquisition to adult-like levels (Figure 5C). Thus, neonatal 
FigUre 4 | cD39 and cD73 expression varies on different subsets of adult B cells. Surface protein was evaluated by flow cytometry [CD39 in (a,c), CD73 
in (B,D)] and mRNA from FACS-isolated B cell subsets was evaluated by reverse transcription and qPCR (e,F). (a,B) are representative of, and (c,D) quantitative 
analysis of, N = 9 adult subjects, statistical analysis repeated measures ANOVA with Holm–Sidak multiple comparison correction. (e,F) N = 5–9 (nine adults 
evaluated, insufficient numbers of plasmablasts for analysis of some samples). Statistical analysis by paired Student’s t-test, bars represent population means and 
error lines are standard error means (SEM), *p < 0.05, **p < 0.01, ***p < 0.001.
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deficiency of naïve B cell CD73 expression functionally limits 
acquisition of extracellular purines.
DiscUssiOn
Neonatal circulating naïve B cells have a significant and selective 
deficiency of the purine enzyme CD73 relative to adult counter-
parts, which we have demonstrated at the level of mRNA expres-
sion, surface protein expression, and enzyme activity. After entry 
to the circulation, expression of CD73 and CD39 is also regulated 
during stages of maturation of B cells potentially impacting B cell 
activity.
Our results represent the most thorough characterization of 
human newborn B cell purine metabolism to date and suggest 
significant and selective differences between human and murine 
B cells in stage-specific expression of CD73. In mice, CD73 is 
expressed primarily on B cells that have undergone class-switch 
recombination (12), and is used as marker of memory (13, 14), 
whereas our data indicate that among circulating human B 
cells CD73 is expressed at the highest levels on naïve cells, with 
 moderate reductions in expression on IgD+ memory cells. Murine 
germinal center B cells express high levels of CD73 (15), whereas 
in humans CD73 is expressed on very few B cells in germinal 
centers (20). These species-specific differences highlighting the 
importance of assessing findings from animal model systems in 
primary human samples.
In addition to differences in mRNA and protein expression, 
we also demonstrated for the first time that neonatal naïve 
B cell CD73 deficiency significantly impaired their capacity 
to acquire extracellular purines for purine salvage. Charged 
nucleotides are not transported across cell membranes; but 
after complete de-phosphorylation, purine and pyrimidine 
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FigUre 5 | neonatal naïve B cells demonstrate lower levels of cD73-mediated ado generation, and subsequently lower levels of ado uptake. (a) 
Isolated neonatal and adult naïve B cells were incubated with radio-labeled adenosine mono-phosphate (C14-AMP) to observe the rate of CD73-mediated adenosine 
generation. Purine composition of the extracellular supernatant was evaluated by thin-layer chromatography, and cellular uptake of radio-labeled purine nucleosides 
was measured in cell fractions using liquid scintillation. Positions for AMP, Ado, and Inosine (Ino) were determined using radiolabeled controls. (a) is 1 representative 
of four to six thin-layer chromatographs of extracellular fluid, (B) is quantitative analysis of chromatographs for N = 6 newborn and N = 4 adult subjects. (c) is 
quantitative analysis of C14 purine uptake into cell fractions for N = 6 newborn and N = 4 adult subjects. Impaired neonatal AMP de-phosphorylation and purine 
acquisition can be overcome by the addition of exogenous recombinant CD73 protein. Statistical analysis by Student’s t-test, unpaired for newborn vs. adult, paired 
for newborn control vs. newborn with rCD73, bars represent population means and error lines are standard error means (SEM), **p < 0.01, ***p < 0.001.
nucleosides can be acquired from the extracellular environment. 
The de-phosphorylation of AMP to generate the purine nucleo-
side Ado is primarily mediated by the enzymes CD73 or TNAP, 
of which B cells express CD73. Purine salvage is considerably 
more energy efficient than de novo purine synthesis and, thus, 
acquiring extracellular purine nucleosides may be critical dur-
ing lymphocyte expansion. Activated T cells rapidly up-regulate 
glucose acquisition systems to meet energy demands (21), and 
lymphocyte activation and clonal expansion require increased 
biosynthesis of nucleic acids and other cellular building blocks 
(22). Incorporation and purine salvage of extracellular Ado by 
resting lymphocytes, and to a much greater degree in proliferat-
ing lymphocytes, have previously been demonstrated (23), and 
purine enzyme activity may be rate-limiting in the generation 
of accessible purine nucleosides for purine salvage. Future stud-
ies will evaluate the contribution of CD73 to the energy status 
and biosynthetic capacity of lymphocytes via purine nucleoside 
mobilization.
FigUre 6 | Model comparing neonatal and adult naïve B cell purine metabolism. Charged purine nucleotides are not acquired via nucleoside transporters 
(equilibrative nucleoside transporters, ENTs) or concentrative nucleoside transporters (CNTs) and require de-phosphorylation prior to uptake of nucleosides. 
Newborn (a) and Adult (B) naïve B cells express similar levels of CD39 and dephosphorylate ADP/ATP to generate AMP, but newborn naïve B cells have low 
expression of CD73 and, therefore, a reduced capacity to dephosphorylate AMP to generate the nucleoside Ado which can be internalized.
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neonatal B cells to lymphoid tissues.
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